Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study

Victoria D. Ojeda, K. Rivet Amico, James P. Hughes, Ethan Wilson, Maoji Li, Timothy H. Holtz, Anupong Chitwarakorn, Robert M. Grant, Bonnie J. Dye, Linda Gail Bekker, Sharon Mannheimer, Mark A Marzinke, Craig Hendrix

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: We evaluated the relationship between 2 types of social relationships, ie, (1) external support for use of HIV pre-exposure prophylaxis (PrEP) and related study supplies and (2) participants' disclosure of PrEP use and condom use and HIV PrEP adherence among daily-dosing regimen participants in HIV Prevention Trials Network (HPTN) 067, an open-label trial of oral tenofovir (TFV) disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg. METHODS: Using HPTN 067 survey data, we developed scales examining (1) Low Perceived External Support for PrEP: low perceived support by others for PrEP use or perceived negative reactions to the pill case (scoring ranges from 0 to 2) and (2) Participant-Staff Disclosure Challenges Scale, which identifies challenges to sharing nonuse of PrEP or condoms to study staff (scoring ranges from 0 to 4); these scales are the primary independent variables. Adherence, the dependent variable, was determined using log-transformed plasma TFV concentrations. generalized estimating equation (GEE) linear regression was used to assess the association between both scales and adherence. RESULTS: Participants (n = 161) included HIV-uninfected women in South Africa, and men who have sex with men and transgender women, in Thailand and the United States. In multivariable analyses, higher scores in the Participant-Staff Disclosure Challenges Scale were significantly associated with lower PrEP adherence [exp(β) = 0.62, 95% CI: (0.46 to 0.84); P = 0.002] as were increased days since the last PrEP dose [exp(β) = 0.73, 95% CI: (0.65 to 0.83); P ≤ 0.001]. CONCLUSIONS: Given the association with adherence, study staff-participant interactions and participants' disclosure of PrEP challenges may be worthwhile intervention targets for improving PrEP adherence in confirmatory studies.

Original languageEnglish (US)
Pages (from-to)34-40
Number of pages7
JournalJournal of acquired immune deficiency syndromes (1999)
Volume82
Issue number1
DOIs
StatePublished - Sep 1 2019

Fingerprint

Disclosure
Risk-Taking
HIV
Tenofovir
Condoms
Pre-Exposure Prophylaxis
Transgender Persons
Thailand
South Africa
Linear Models

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study. / Ojeda, Victoria D.; Amico, K. Rivet; Hughes, James P.; Wilson, Ethan; Li, Maoji; Holtz, Timothy H.; Chitwarakorn, Anupong; Grant, Robert M.; Dye, Bonnie J.; Bekker, Linda Gail; Mannheimer, Sharon; Marzinke, Mark A; Hendrix, Craig.

In: Journal of acquired immune deficiency syndromes (1999), Vol. 82, No. 1, 01.09.2019, p. 34-40.

Research output: Contribution to journalArticle

Ojeda, Victoria D. ; Amico, K. Rivet ; Hughes, James P. ; Wilson, Ethan ; Li, Maoji ; Holtz, Timothy H. ; Chitwarakorn, Anupong ; Grant, Robert M. ; Dye, Bonnie J. ; Bekker, Linda Gail ; Mannheimer, Sharon ; Marzinke, Mark A ; Hendrix, Craig. / Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study. In: Journal of acquired immune deficiency syndromes (1999). 2019 ; Vol. 82, No. 1. pp. 34-40.
@article{667137cb5b11456885bcce7d49030779,
title = "Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study",
abstract = "OBJECTIVE: We evaluated the relationship between 2 types of social relationships, ie, (1) external support for use of HIV pre-exposure prophylaxis (PrEP) and related study supplies and (2) participants' disclosure of PrEP use and condom use and HIV PrEP adherence among daily-dosing regimen participants in HIV Prevention Trials Network (HPTN) 067, an open-label trial of oral tenofovir (TFV) disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg. METHODS: Using HPTN 067 survey data, we developed scales examining (1) Low Perceived External Support for PrEP: low perceived support by others for PrEP use or perceived negative reactions to the pill case (scoring ranges from 0 to 2) and (2) Participant-Staff Disclosure Challenges Scale, which identifies challenges to sharing nonuse of PrEP or condoms to study staff (scoring ranges from 0 to 4); these scales are the primary independent variables. Adherence, the dependent variable, was determined using log-transformed plasma TFV concentrations. generalized estimating equation (GEE) linear regression was used to assess the association between both scales and adherence. RESULTS: Participants (n = 161) included HIV-uninfected women in South Africa, and men who have sex with men and transgender women, in Thailand and the United States. In multivariable analyses, higher scores in the Participant-Staff Disclosure Challenges Scale were significantly associated with lower PrEP adherence [exp(β) = 0.62, 95{\%} CI: (0.46 to 0.84); P = 0.002] as were increased days since the last PrEP dose [exp(β) = 0.73, 95{\%} CI: (0.65 to 0.83); P ≤ 0.001]. CONCLUSIONS: Given the association with adherence, study staff-participant interactions and participants' disclosure of PrEP challenges may be worthwhile intervention targets for improving PrEP adherence in confirmatory studies.",
author = "Ojeda, {Victoria D.} and Amico, {K. Rivet} and Hughes, {James P.} and Ethan Wilson and Maoji Li and Holtz, {Timothy H.} and Anupong Chitwarakorn and Grant, {Robert M.} and Dye, {Bonnie J.} and Bekker, {Linda Gail} and Sharon Mannheimer and Marzinke, {Mark A} and Craig Hendrix",
year = "2019",
month = "9",
day = "1",
doi = "10.1097/QAI.0000000000002103",
language = "English (US)",
volume = "82",
pages = "34--40",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study

AU - Ojeda, Victoria D.

AU - Amico, K. Rivet

AU - Hughes, James P.

AU - Wilson, Ethan

AU - Li, Maoji

AU - Holtz, Timothy H.

AU - Chitwarakorn, Anupong

AU - Grant, Robert M.

AU - Dye, Bonnie J.

AU - Bekker, Linda Gail

AU - Mannheimer, Sharon

AU - Marzinke, Mark A

AU - Hendrix, Craig

PY - 2019/9/1

Y1 - 2019/9/1

N2 - OBJECTIVE: We evaluated the relationship between 2 types of social relationships, ie, (1) external support for use of HIV pre-exposure prophylaxis (PrEP) and related study supplies and (2) participants' disclosure of PrEP use and condom use and HIV PrEP adherence among daily-dosing regimen participants in HIV Prevention Trials Network (HPTN) 067, an open-label trial of oral tenofovir (TFV) disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg. METHODS: Using HPTN 067 survey data, we developed scales examining (1) Low Perceived External Support for PrEP: low perceived support by others for PrEP use or perceived negative reactions to the pill case (scoring ranges from 0 to 2) and (2) Participant-Staff Disclosure Challenges Scale, which identifies challenges to sharing nonuse of PrEP or condoms to study staff (scoring ranges from 0 to 4); these scales are the primary independent variables. Adherence, the dependent variable, was determined using log-transformed plasma TFV concentrations. generalized estimating equation (GEE) linear regression was used to assess the association between both scales and adherence. RESULTS: Participants (n = 161) included HIV-uninfected women in South Africa, and men who have sex with men and transgender women, in Thailand and the United States. In multivariable analyses, higher scores in the Participant-Staff Disclosure Challenges Scale were significantly associated with lower PrEP adherence [exp(β) = 0.62, 95% CI: (0.46 to 0.84); P = 0.002] as were increased days since the last PrEP dose [exp(β) = 0.73, 95% CI: (0.65 to 0.83); P ≤ 0.001]. CONCLUSIONS: Given the association with adherence, study staff-participant interactions and participants' disclosure of PrEP challenges may be worthwhile intervention targets for improving PrEP adherence in confirmatory studies.

AB - OBJECTIVE: We evaluated the relationship between 2 types of social relationships, ie, (1) external support for use of HIV pre-exposure prophylaxis (PrEP) and related study supplies and (2) participants' disclosure of PrEP use and condom use and HIV PrEP adherence among daily-dosing regimen participants in HIV Prevention Trials Network (HPTN) 067, an open-label trial of oral tenofovir (TFV) disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg. METHODS: Using HPTN 067 survey data, we developed scales examining (1) Low Perceived External Support for PrEP: low perceived support by others for PrEP use or perceived negative reactions to the pill case (scoring ranges from 0 to 2) and (2) Participant-Staff Disclosure Challenges Scale, which identifies challenges to sharing nonuse of PrEP or condoms to study staff (scoring ranges from 0 to 4); these scales are the primary independent variables. Adherence, the dependent variable, was determined using log-transformed plasma TFV concentrations. generalized estimating equation (GEE) linear regression was used to assess the association between both scales and adherence. RESULTS: Participants (n = 161) included HIV-uninfected women in South Africa, and men who have sex with men and transgender women, in Thailand and the United States. In multivariable analyses, higher scores in the Participant-Staff Disclosure Challenges Scale were significantly associated with lower PrEP adherence [exp(β) = 0.62, 95% CI: (0.46 to 0.84); P = 0.002] as were increased days since the last PrEP dose [exp(β) = 0.73, 95% CI: (0.65 to 0.83); P ≤ 0.001]. CONCLUSIONS: Given the association with adherence, study staff-participant interactions and participants' disclosure of PrEP challenges may be worthwhile intervention targets for improving PrEP adherence in confirmatory studies.

UR - http://www.scopus.com/inward/record.url?scp=85071351349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071351349&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000002103

DO - 10.1097/QAI.0000000000002103

M3 - Article

C2 - 31169769

AN - SCOPUS:85071351349

VL - 82

SP - 34

EP - 40

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -